I have a concern around this shortage being only temporarily resolved, and there being sort of a yo-yo effect of the shortage coming and going over the next year
Integration of GLP-1RAs with advanced nanoplatforms holds great promise to transform the therapeutic landscape of PD by enabling multifaceted intervention at cellular and molecular levels
Unlike direct GH therapy, Sermorelin rarely causes significant fluid retention, carpal tunnel syndrome, joint pain, or severe insulin resistance that can complicate GH replacement, though mild versions of these effects are theoretically possible if GH stimulation is excessive
It is an emollient and emulsifier
GLP-1 manufacturers are giving us all the drama we need
Size and scope differ, but neither factor determines clinical results